Abecma (idecabtagene vicleucel)
Drug company: Bristol Myers Squibb/Bluebird Bio
888-805-4555
Bristol Myers Squibb, through Cell Therapy 360, offers 2 financial assistance programs to patients using Abecma:
Cell Therapy 360 Copay Program
Cell Therapy 360 Patient Assistance Program
Carvykti (ciltacabtagene autoleucel)
Drug company: Janssen Biotech
800-559-7875
Janssen Biotech offers 1 financial assistance program for patients using Carvykti:
MyCARVYKTI Patient Support Program
Darzalex (daratumumab) Intravenous Injection
Drug company: Janssen Biotech
844-553-2792
Janssen Biotech offers 3 financial assistance programs for patients using Darzalex:
Janssen CarePath Savings Program
Johnson & Johnson Patient Assistance Foundation
Janssen Compass
Darzalex Faspro (daratumumab & hyaluronidase-fihj) Subcutaneous Injection
Drug company: Janssen Biotech
844-553-2792
Janssen Biotech offers 3 financial assistance programs for patients who have been prescribed Darzalex Faspro:
Janssen CarePath Savings Program
Johnson & Johnson Patient Assistance Foundation
Janssen Compass
Empliciti (elotuzumab)
Drug company: Bristol Myers Squibb
800-861-0048
Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Empliciti:
BMS Oncology Co-Pay Assistance Program
Bristol Myers Squibb Patient Assistance Foundation
Evomela (melphalan) Injection
Drug company: Acrotech Biopharma
888-537-8277
Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients receiving Evomela:
STAR Co-pay Assistance
STAR Patient Assistance Program
Kyprolis (carfilzomib) Injection
Drug company: Amgen
888-427-7478
Amgen Assist 360 offers 3 financial assistance programs for patients using Kyprolis:
Amgen FIRST STEP Co-Pay Program
Amgen Assist 360
Amgen Safety Net Foundation
Mozobil (plerixafor) Injection
Drug company: Sanofi Aventis
888-847-4877
Sanofi Aventis, through Sano Cares North America, offers 1 financial assistance program to patients using Mozobil:
Sanofi Patient Assistance Connection
Ninlaro (ixazomib) Capsules
Drug company: Takeda Oncology
844-617-6468
Takeda Oncology offers 2 financial assistance programs for patients using Ninlaro:
Takeda Oncology Co-Pay Assistance Program
Takeda Oncology Patient Assistance Program
Pomalyst (pomalidomide) Capsules
Drug company: Bristol Myers Squibb
800-861-0048
Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Pomalyst:
BMS Oncology Co-Pay Assistance Program
Bristol Myers Squibb Patient Assistance Foundation
Revlimid (lenalidomide) Capsules
Drug company: Bristol Myers Squibb
800-861-0048
Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Revlimid:
BMS Oncology Co-Pay Assistance Program
Bristol Myers Squibb Patient Assistance Foundation
Sarclisa (isatuximab-irfc) Injection
Drug company: Sanofi Genzyme
833-930-2273
Sanofi Genzyme offer 2 financial assistance programs for patients who have been prescribed Sarclisa:
CareASSIST Copay Program
CareASSIST Patient Assistance Program
Tecvayli (teclistamab-cqyv) Injection
Drug company: Janssen Biotech
877-277-3728
Janssen Biotech offers 3 financial assistance programs for patients using Tecvayli:
Janssen CarePath Savings Program
Johnson & Johnson Patient Assistance Foundation
Janssen Compass
Thalomid (thalidomide) Capsules
Drug company: Bristol Myers Squibb
800-861-0048
Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Thalomid:
BMS Oncology Co-Pay Assistance Program
Bristol Myers Squibb Patient Assistance Foundation
Velcade (bortezomib) Injection
Drug company: Takeda Oncology
844-617-6468
Takeda Oncology offers 2 financial assistance programs for patients using Velcade:
Velcade Reimbursement Assistance Program
Velcade Patient Assistance Program
Xpovio (selinexor) Tablets
Drug company: Karyopharm Therapeutics
877-527-9493
Karyopharm Therapeutics offers 3 financial assistance programs for patients who have been prescribed Xpovio:
Xpovio Copay Card Program
Xpovio QuickStart
Xpovio Patient Assistance Program
Table. Drugs Prescribed for Multiple Myeloma
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Abecma (idecabtagene vicleucel)
- Bristol Myers Squibb/Bluebird Bio
- Treatment of adults with relapsed or refractory multiple myeloma after 4 or more previous lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
- Cell Therapy 360 Copay Program
888-805-4555
Cell Therapy 360 Patient Assistance Program
888-805-4555
Drug name (generic name)
Drug company
Indication
Patient support services
- Carvykti (ciltacabtagene autoleucel)
- Janssen Biotech
- Treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
- MyCARVYKTI Patient
Support Program
800-559-7875
Drug name (generic name)
Drug company
Indication
Patient support services
- Darzalex (daratumumab) Intravenous Injection
- Janssen Biotech
- Treatment of multiple myeloma,
in combination with Revlimid and
dexamethasone, in newly diagnosed
patients who are ineligible for autologous
stem-cell transplant, and in
patients with relapsed or refractory
multiple myeloma who have received
at least 1 previous therapy
Treatment of multiple myeloma, in combination with Velcade, melphalan, and prednisone, in newly diagnosed patients who are ineligible for autologous stem-cell transplant
Treatment of multiple myeloma, in combination with Velcade, thalidomide, and dexamethasone, in newly diagnosed patients who are eligible for autologous stem-cell transplant
Treatment of multiple myeloma, in combination with Revlimid and dexamethasone, or with Velcade and dexamethasone, after 1 therapy
Treatment of multiple myeloma, in combination with Pomalyst and dexamethasone, after 2 therapies
Treatment of multiple myeloma, as monotherapy, after 3 therapies - Janssen CarePath Savings Program
844-553-2792
Johnson & Johnson Patient Assistance Foundation
800-652-6227
Janssen Compass
844-628-1234
Drug name (generic name)
Drug company
Indication
Patient support services
- Darzalex Faspro (daratumumab & hyaluronidase-fihj) Subcutaneous Injection
- Janssen Biotech
- First-line treatment, in combination
with Velcade, melphalan, and
prednisone, of patients who are
ineligible for a transplant
Treatment, in combination with Revlimid and dexamethasone, of newly diagnosed patients who are ineligible for a transplant, or patients with relapsed or refractory multiple myeloma who have received at least 1 therapy
Treatment, in combination with Velcade and dexamethasone, of patients who have received at least 1 previous therapy
As monotherapy for patients who have received at least 3 previous lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who are double-refractory to a proteasome inhibitor and an immunomodulatory drug
Treatment, in combination with Velcade, thalidomide, and dexamethasone, of newly diagnosed patients eligible for autologous stem-cell transplant
Treatment, in combination with Pomalyst and dexamethasone, of patients who have received at least 1 previous line of therapy, including Revlimid and a proteasome inhibitor - Janssen CarePath Savings Program
844-553-2792
Johnson & Johnson Patient Assistance Foundation
800-652-6227
Janssen Compass
844-628-1234
Drug name (generic name)
Drug company
Indication
Patient support services
- Empliciti (elotuzumab)
- Bristol Myers Squibb
- Multiple myeloma, in combination
with Revlimid and dexamethasone,
after 1 to 3 therapies
Multiple myeloma, in combination with Pomalyst and dexamethasone, after 2 therapies, including Revlimid and a proteasome inhibitor - BMS Oncology Co-Pay Assistance Program
800-861-0048
Bristol Myers Squibb Patient Assistance Foundation
800-736-0003
Drug name (generic name)
Drug company
Indication
Patient support services
- Evomela (melphalan) Injection
- Acrotech Biopharma
- Conditioning treatment before
stem-cell transplant in patients with
multiple myeloma
Palliative treatment for patients with multiple myeloma - STAR Co-pay Assistance
888-537-8277
STAR Patient Assistance Program
888-537-8277
Drug name (generic name)
Drug company
Indication
Patient support services
- Kyprolis (carfilzomib) Injection
- Amgen
- Relapsed or refractory multiple myeloma, as a single agent or in combination with dexamethasone or with Revlimid plus dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone, after 1-3 therapies
- Amgen FIRST STEP Co-Pay Program
866-264-2778
Amgen Assist 360
888-427-7478
Amgen Safety Net Foundation
866-264-2778
Drug name (generic name)
Drug company
Indication
Patient support services
- Mozobil (plerixafor) Injection
- Sanofi Aventis
- Treatment of multiple myeloma, in combination with granulocyte colony-stimulating factor, after autologous stem-cell transplant
- Sanofi Patient Assistance Connection
888-847-4877
Drug name (generic name)
Drug company
Indication
Patient support services
- Ninlaro (ixazomib) Capsules
- Takeda Oncology
- Multiple myeloma, in combination with Revlimid and dexamethasone
- Takeda Oncology Co-Pay Assistance Program
844-817-6468
Takeda Oncology Patient Assistance Program
844-817-6468
Drug name (generic name)
Drug company
Indication
Patient support services
- Pomalyst (pomalidomide) Capsules
- Bristol Myers Squibb
- Multiple myeloma, in combination with
dexamethasone, after 2 therapies
Multiple myeloma, in combination with Empliciti and dexamethasone, after other therapies - BMS Oncology Co-Pay Assistance Program
800-861-0048
Bristol Myers Squibb Patient Assistance Foundation
800-736-0003
Drug name (generic name)
Drug company
Indication
Patient support services
- Revlimid (lenalidomide) Capsules
- Bristol Myers Squibb
- Multiple myeloma, in combination with
dexamethasone
Multiple myeloma, as maintenance therapy after stem-cell transplant - BMS Oncology Co-Pay Assistance Program
800-861-0048
Bristol Myers Squibb Patient Assistance Foundation
800-736-0003
Drug name (generic name)
Drug company
Indication
Patient support services
- Sarclisa (isatuximab-irfc) Injection
- Sanofi Genzyme
- Treatment, in combination with
Pomalyst and dexamethasone, of
adults with multiple myeloma who
have received at least 2 therapies that
include Revlimid and a proteasome
inhibitor
Treatment, in combination with Kyprolis and dexamethasone, of adults with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy - CareASSIST Copay Program
833-930-2273
CareASSIST Patient Assistance Program
833-930-2273
Drug name (generic name)
Drug company
Indication
Patient support services
- Tecvayli (teclistamabcqyv) Injection
- Janssen Biotech
- Treatment of adult patients with relapsed or refractory multiple myeloma who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
- Janssen CarePath
Savings Program
877-277-3728
Johnson & Johnson Patient Assistance Foundation
800-652-6227
Janssen Compass
844-628-1234
Drug name (generic name)
Drug company
Indication
Patient support services
- Thalomid (thalidomide) Capsules
- Bristol Myers Squibb
- Newly diagnosed multiple myeloma, in combination with dexamethasone
- BMS Oncology Co-Pay Assistance Program
800-861-0048
Bristol Myers Squibb Patient Assistance Foundation
800-736-0003
Drug name (generic name)
Drug company
Indication
Patient support services
- Velcade (bortezomib) Injection
- Takeda Oncology
- Multiple myeloma, alone or in combination with other therapies
- Velcade
Reimbursement
Assistance Program
844-817-6468
Velcade Patient Assistance Program
844-817-6468
Drug name (generic name)
Drug company
Indication
Patient support services
- Xpovio (selinexor) Tablets
- Karyopharm Therapeutics
- Treatment of relapsed or refractory
multiple myeloma, after at
least 4 previous therapies and
disease refractory to at least 2
proteasome inhibitors, at least 2
immunomodulatory agents, and an
anti-CD38 monoclonal antibody
Treatment, in combination with Velcade and dexamethasone, for adults with multiple myeloma who have received at least 1 previous therapy - Xpovio Copay Card Program
844-243-7949
Xpovio Quick Start
877-527-9493
Xpovio Patient Assistance Program
Drug name (generic name)
Drug company
Indication
Patient support services